Sound biological rationale exists for the co-administration of docetaxel plus abiraterone and prednisone as a treatment regimens for patients with metastatic castration-resistant prostate cancer (mCRPC). Newly published results from a phase Ib dose-escalation study in three cohorts of men with chemotherapy naïve mCRPC suggest a recommended phase II dose of 75 mg/m² docetaxel, 1,000 mg abiraterone, plus 10 mg prednisone. Investigators reported a high rate of serum PSA decline; however, the efficacy of this approach will require further investiation in later-phase clinical trials.